UC AKT.ANL. 08/25 MRK/ DE000HD1JVN5 /
1/24/2025 9:47:01 PM | Chg.+0.020 | Bid9:59:26 PM | Ask9:59:26 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
100.450EUR | +0.02% | 100.220 Bid Size: 70,000 |
100.650 Ask Size: 70,000 |
MERCK KGAA O.N. | 110.00 - | 8/22/2025 | Call |
GlobeNewswire
6/3/2024
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
5/29/2024
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
5/29/2024
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
GlobeNewswire
5/7/2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
5/6/2024
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
3/4/2024
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
12/21/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
12/14/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
10/17/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA